



Universiteit  
Leiden  
The Netherlands

## **Design of novel TCR gene transfer strategies for the treatment of hematological malignancies**

Veken, L.T.J.N. van der

### **Citation**

Veken, L. T. J. N. van der. (2009, September 8). *Design of novel TCR gene transfer strategies for the treatment of hematological malignancies*. Retrieved from <https://hdl.handle.net/1887/13964>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/13964>

**Note:** To cite this publication please use the final published version (if applicable).

# **Design of novel TCR gene therapy strategies for the treatment of hematological malignancies**

**Lars van der Veken**



# **Design of novel TCR gene therapy strategies for the treatment of hematological malignancies**

## **Proefschrift**

ter verkrijging van

de graad van Doctor aan de Universiteit van Leiden,

op gezag van Rector Magnificus prof.mr. P.F. van der Heijden,

volgens het besluit van het College voor Promoties

te verdedigen op dinsdag 8 september 2009

klokke 15.00 uur

door

Lars Thomas Johannes Nicolaas van der Veken

geboren te Etten-Leur

in 1977

## Promotiecommissie

Promotor	Prof. Dr. J.H.F. Falkenburg
Co-promotor	Dr. M.H.M. Heemskerk
Overige leden	Prof. Dr. J.B.A.G. Haanen Prof. Dr. F. Koning Prof. Dr. M. Theobald, <i>Universitair Medisch Centrum Utrecht</i>

© Lars T.J.N. van der Veken, 2009

ISBN/EAN: 978-90-9024368-9

Cover: Structure of a human TCR interacting with a HLA-A\*0201 molecule presenting a viral peptide (Tax). The image was generated using Cn3D v4.0 software, National Center for Biotechnology Information, <http://www.ncbi.nlm.nih.gov>

Printing: Roto Smeets GrafiServices, Utrecht

The work described in this thesis was financially supported by the Dutch Cancer Society (KWF).

Financial support for the printing of this thesis was provided by the Dutch Cancer Society (KWF), J.E. Jurriaanse stichting, and Greiner bio-one.





# Design of novel TCR gene therapy strategies for the treatment of hematological malignancies

## Contents

<b>Chapter 1</b>	<b>Introduction</b>	<b>9</b>
<b>Chapter 2</b>	<b>HLA class II restricted T cell receptor gene transfer generates CD4<sup>+</sup> T cells with helper activity as well as cytotoxic capacity</b> <i>Gene Ther. 2005 Dec;12(23):1686-95</i>	<b>31</b>
<b>Chapter 3</b>	<b><math>\alpha\beta</math> T cell receptor engineered <math>\gamma\delta</math> T cells mediate effective antileukemic reactivity</b> <i>Cancer Res. 2006 Mar 15;66(6):3331-7</i>	<b>51</b>
<b>Chapter 4</b>	<b><math>\alpha\beta</math> T cell receptor transfer to <math>\gamma\delta</math> T cells generates functional effector cells without mixed TCR dimers <i>in vivo</i></b> <i>J Immunol. 2009 Jan 1;182(1):164-70</i>	<b>69</b>
<b>Chapter 5</b>	<b>Functional analysis of Killer Ig-like receptor-expressing cytomegalovirus-specific CD8<sup>+</sup> T cells</b> <i>J Immunol. 2009 Jan 1;182(1):92-101</i>	<b>87</b>
<b>Chapter 6</b>	<b>Summary &amp; General discussion</b>	<b>109</b>
<b>Chapter 7</b>	<b>Nederlandse samenvatting</b>	<b>125</b>
	<b>Nawoord</b>	<b>135</b>
	<b>Publications</b>	<b>137</b>
	<b>Curriculum Vitae</b>	<b>139</b>



